Oruka Therapeutics (NASDAQ:ORKA) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $45.00 target price on the stock.

Other equities research analysts also recently issued reports about the stock. Jefferies Financial Group began coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 target price for the company. Lifesci Capital assumed coverage on shares of Oruka Therapeutics in a research note on Monday, September 16th. They set an “outperform” rating and a $41.00 price objective for the company. Leerink Partners assumed coverage on Oruka Therapeutics in a research report on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 target price on the stock. Leerink Partnrs raised Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Stifel Nicolaus initiated coverage on Oruka Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $43.17.

Oruka Therapeutics Trading Down 2.2 %

Shares of NASDAQ:ORKA opened at $20.31 on Friday. The firm has a market cap of $710.83 million, a price-to-earnings ratio of -3.24 and a beta of 0.78. The stock has a 50-day simple moving average of $24.55. Oruka Therapeutics has a 12-month low of $18.20 and a 12-month high of $53.88.

Institutional Investors Weigh In On Oruka Therapeutics

A number of large investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company purchased a new position in Oruka Therapeutics in the 3rd quarter worth approximately $1,037,000. Wellington Management Group LLP acquired a new position in shares of Oruka Therapeutics during the third quarter worth $2,013,000. Point72 Asset Management L.P. purchased a new position in shares of Oruka Therapeutics in the third quarter valued at $11,822,000. RTW Investments LP acquired a new stake in Oruka Therapeutics during the 3rd quarter valued at $45,359,000. Finally, FMR LLC purchased a new stake in Oruka Therapeutics during the 3rd quarter worth $114,763,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.